approval
saveOZURDEX (DEXAMETHASONE) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
view source ↗Data sources
last refreshed 6mo ago
Found something off?
drug timeline · 8
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalMar 11, 2026 · 254d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalDec 19, 2022 · 1432d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalOct 21, 2020 · 2221d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalMay 15, 2018 · 3111d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalFeb 5, 2016 · 3941d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalSep 26, 2014 · 4438d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalJun 28, 2014 · 4528d ago
- approvalOZURDEX (DEXAMETHASONE) — FDA approvalFeb 7, 2014 · 4669d ago
same company · ±60 days · 6
- earningsAbbVie Inc. earningsOct 30, 2026
- earningsAbbVie Inc. earningsOct 29, 2026
- earningsAbbVie Inc. earningsJul 31, 2026
- earningsAbbVie Inc. earningsJul 30, 2026
- phase 1 2 completionblinatumomab: AbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026
- phase 1 2 completionvenetoclax: AbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026
related news · 8
- biospaceFDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
- fiercebiotechFDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
- biopharma diveAt ASH, drugmakers to showcase early data for three-pronged cancer therapies
- fiercebiotechAbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
- biospaceAbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
- fiercebiotechAbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations
- biospaceAs AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
- endpointsAbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
comments(0)
5-min edit window · permanent after that